SS-31 Dosage Protocol: What Research Shows About Dosing

There is no FDA-approved SS-31 dosage protocol for human use in the United States. In published clinical trials, elamipretide (the research name for SS-31) has most often been given as a 40 mg subcutaneous injection once daily, while community research-peptide protocols typically describe far smaller amounts, usually in the 1–10 mg per day range. Because SS-31 is an investigational compound, any dosing decision should be made with a licensed healthcare professional.

What SS-31 (Elamipretide) Actually Is

SS-31 is a short synthetic tetrapeptide designed to concentrate inside mitochondria and bind to cardiolipin, a phospholipid in the inner mitochondrial membrane. Researchers study it in conditions where mitochondrial energy production is impaired, including Barth syndrome, primary mitochondrial myopathy, and dry age-related macular degeneration.

Elamipretide is the international nonproprietary name for SS-31, and the two terms are used interchangeably in the literature. That is why a search for one name usually surfaces results for the other.

Key facts to keep in mind:

• SS-31 is a research peptide, not a dietary supplement.
• It is injected in studies because oral bioavailability is poor.
• Most human data come from small trials sponsored by a single drug developer.

Clinical Trial Doses of Elamipretide

Doses used in human research are the closest thing to an evidence-based protocol. The table below summarizes what has been published in peer-reviewed trials.

Program	Population	Dose Studied	Route
TAZPOWER	Barth syndrome	40 mg once daily	Subcutaneous
MMPOWER-3	Primary mitochondrial myopathy	40 mg once daily	Subcutaneous
ReCLAIM / ReCLAIM-2	Dry age-related macular degeneration	40 mg once daily	Subcutaneous
Early cardiac studies	Heart attack and heart failure	Weight-based infusion (mg/kg/hr)	Intravenous

The 40 mg daily subcutaneous dose is the most consistently studied schedule in humans. Even so, results have been mixed: an FDA advisory committee questioned whether the Barth syndrome data demonstrated meaningful benefit, and the compound has not been approved for any indication.

Community Research Dosing Ranges

Outside of clinical trials, most of what circulates online as an ss-31 peptide dosage reflects animal studies, anecdotal reports, and vendor marketing rather than controlled human data. Reported ranges are wide and are not established medical standards.

Parameter	Commonly Reported in Research-Peptide Communities
Daily amount	1–10 mg per day
Frequency	Once daily, subcutaneous
Cycle length	4–8 weeks on, often followed by a break
Typical vial size	10 mg lyophilized powder
Timing	Usually morning, sometimes before exercise

Animal studies frequently used 1–5 mg/kg, and that figure does not translate simply into a human milligram dose. There is no validated conversion formula, so any number borrowed from a rodent study should be treated as a rough reference point at best.

Reconstitution Math: Turning Milligrams Into Syringe Units

Getting the arithmetic right matters, which is why ss-31 reconstitution and dosage are usually discussed together. A 10 mg vial diluted with 2 mL of bacteriostatic water yields 5 mg/mL, or 5,000 mcg/mL.

• 1 mg = 0.2 mL = 20 units on a U-100 insulin syringe.
• 5 mg = 1.0 mL = 100 units.
• Adding more water lowers the concentration; adding less raises it.

An ss-31 dosage calculator can help you convert milligrams into syringe units, but it cannot tell you what amount is safe or appropriate for you. Always verify the math by hand, because a misplaced decimal in peptide calculations can produce a tenfold error.

Stacking: SS-31 Combined With Other Peptides

Some people combine mitochondrial peptides, and an ss-31 and mots-c protocol is often discussed in the same breath. MOTS-c is a mitochondrial-derived peptide studied for metabolic effects, and there is no published human trial testing the two compounds together.

Other compounds frequently mentioned alongside SS-31 include NAD+, BPC-157, and TB-500. None of these combinations have been evaluated for safety in humans, and stacking raises the odds of an unexpected reaction or of a mislabeled product entering the mix.

Side Effects, Legal Status, and Safety

In clinical trials, the most commonly reported side effects of elamipretide were injection-site reactions such as redness, pain, and swelling. Headache and nausea were also reported. Serious events were uncommon among the trial participants studied, but those groups were small.

Elamipretide is not FDA-approved for human use in the United States. Peptides sold online for research purposes are generally not manufactured under pharmaceutical-grade oversight, so purity and actual content can differ substantially from the label.

Compounds marketed strictly for research use are not intended for human consumption, and their labeling is not verified by the FDA.

Anyone weighing an ss-31 peptide dosing protocol should first talk with a physician who knows their medical history, current medications, and kidney and liver function. Self-experimentation with unapproved injectables carries real risk, including infection, allergic reaction, and dosing errors.

Bottom Line

The only well-documented human dose of SS-31 is 40 mg injected subcutaneously once daily, studied in trials that did not lead to FDA approval. Community protocols describing lower daily amounts are not supported by controlled human evidence.

SS-31 is an investigational peptide, not an approved therapy. A licensed clinician is the right person to assess whether any dose makes sense for a specific individual.

COMMON QUESTIONS

Frequently Asked Questions

What is the typical SS-31 dosage protocol?

In human clinical trials, elamipretide was most often dosed at 40 mg subcutaneously once daily. Community research-peptide protocols commonly describe much lower amounts, often 1–10 mg per day, but these numbers are not backed by controlled human trials. SS-31 is not FDA-approved, so there is no official dosing schedule.

Is SS-31 FDA approved for human use?

No. Elamipretide, the drug name for SS-31, has not been approved by the FDA for any indication as of this writing. Regulators have raised questions about whether the trial data show meaningful clinical benefit. Peptides sold online for research purposes are not approved for human consumption and are not verified for purity.

Can SS-31 be stacked with MOTS-c?

Some people combine the two mitochondrial peptides, but there is no published human trial testing SS-31 and MOTS-c together. Combining unapproved injectables increases the risk of side effects and makes it harder to identify what is causing a reaction. A physician should review any combination before it is considered.